Back to results
US 11,535,672 B2Granted
Combination of an anti-CD16A antibody with a cytokine
AssigneeAffimed GmbH
InventorsJoachim Koch, Martin Treder, Jens Pahl, Uwe Reusch, Thorsten Ross, Erich Rajkovic, Adelheid Cerwenka
Life of this patent
Estimating the term…
Abstract
The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.
Claims28
A method of NK-cell based immunotherapy for treating cancer,
- comprising administering to a subject in need thereof
- (i) an antigen binding protein comprising at least one antigen binding site formed by a variable heavy chain domain and a variable light chain domain of an immunoglobulin for binding to CD16A to activate cytotoxicity of NK cells through CD16A engagement, and
- (ii) at least one cytokine selected from the group consisting of interleukin 2 (IL-2), interleukin 12 (IL-12), interleukin 15 (IL-15), interleukin 18 (IL-18), and a combination thereof,
- wherein the antigen binding protein is administered intermittently in intervals comprising an exposure free period to the antigen binding protein between two consecutive doses of the antigen binding protein, and wherein the intermittent administration comprises the steps of:
- (a) administering a first dose of the antigen binding protein;
- and
- (b) administering a second dose of the antigen binding protein after at least 3 times the half-life of the antigen binding protein subsequent to step (a), and
- (c) administering a dose of at least one cytokine only during the interval from step (a) to step (b);
- wherein steps (a), (b), and (c) are repeated at least 3 times.
6 more elements
Dependencies are inferred from the claim text.